Halaven

Active Ingredient(s): Eribulin Mesylate
FDA Approved: * November 15, 2010
Pharm Company: * EISAI INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Halaven Overview

Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma. Contents 1 Intellectual Property 2 Approvals and indications 2.1 Breast cancer 2.2 Liposarcoma 3 Clinical trials 4 Research and development 5 Structure and mechanism 6 References 7 External links Intellectual Property Currently ther...

Read more Halaven Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Eribulin

Recent Halaven Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Halaven: (2 results)

Sorted by National Drug Code

• 43624-002 Halaven .5 mg/ml Intravenous Injection by Bsp Pharmaceuticals Spa
• 62856-389 Halaven .5 mg/ml Intravenous Injection by Eisai Inc.

Other drugs which contain Eribulin Mesylate or a similar ingredient: (1 result)

• ERIBULIN MESYLATE